pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-6737 |
Genomic Coordinates | chr1: 153962351 - 153962420 |
Description | Homo sapiens miR-6737 stem-loop |
Comment | None |
RNA Secondary Structure |
Mature miRNA Information | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-6737-5p | |||||||||||||||||||||
Sequence | 6| UUGGGGUGGUCGGCCCUGGAG |26 | |||||||||||||||||||||
Evidence | Experimental | |||||||||||||||||||||
Experiments | Meta-analysis | |||||||||||||||||||||
SNPs in miRNA |
|
|||||||||||||||||||||
Putative Targets |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | NCOA3 | ||||||||||||||||||||
Synonyms | ACTR, AIB-1, AIB1, CAGH16, CTG26, KAT13B, RAC3, SRC-3, SRC3, TNRC14, TNRC16, TRAM-1, bHLHe42, pCIP | ||||||||||||||||||||
Description | nuclear receptor coactivator 3 | ||||||||||||||||||||
Transcript | NM_001174087 | ||||||||||||||||||||
Other Transcripts | NM_001174088 , NM_006534 , NM_181659 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on NCOA3 | |||||||||||||||||||||
3'UTR of NCOA3 (miRNA target sites are highlighted) |
>NCOA3|NM_001174087|3'UTR 1 CATCTCTGCACCAGGACCTCTTAAGGAAACCACTGTACAAATGACACTGCACTAGGATTATTGGGAAGGAATCATTGTTC 81 CAGGCATCCATCTTGGAAGAAAGGACCAGCTTTGAGCTCCATCAAGGGTATTTTAAGTGATGTCATTTGAGCAGGACTGG 161 ATTTTAAGCCGAAGGGCAATATCTACGTGTTTTTCCCCCCTCCTTCTGCTGTGTATCATGGTGTTCAAAACAGAAATGTT 241 TTTTGGCATTCCACCTCCTAGGGATATAATTCTGGAGACATGGAGTGTTACTGATCATAAAACTTTTGTGTCACTTTTTT 321 CTGCCTTGCTAGCCAAAATCTCTTAAATACACGTAGGTGGGCCAGAGAACATTGGAAGAATCAAGAGAGATTAGAATATC 401 TGGTTTCTCTAGTTGCAGTATTGGACAAAGAGCATAGTCCCAGCCTTCAGGTGTAGTAGTTCTGTGTTGACCCTTTGTCC 481 AGTGGAATTGGTGATTCTGAATTGTCCTTTACTAATGGTGTTGAGTTGCTCTGTCCCTATTATTTGCCCTAGGCTTTCTC 561 CTAATGAAGGTTTTCATTTGCCATTCATGTCCTGTAATACTTCACCTCCAGGAACTGTCATGGATGTCCAAATGGCTTTG 641 CAGAAAGGAAATGAGATGACAGTATTTAATCGCAGCAGTAGCAAACTTTTCACATGCTAATGTGCAGCTGAGTGCACTTT 721 ATTTAAAAAGAATGGATAAATGCAATATTCTTGAGGTCTTGAGGGAATAGTGAAACACATTCCTGGTTTTTGCCTACACT 801 TACGTGTTAGACAAGAACTATGATTTTTTTTTTTAAAGTACTGGTGTCACCCTTTGCCTATATGGTAGAGCAATAATGCT 881 TTTTAAAAATAAACTTCTGAAAACCCAAGGCCAGGTACTGCATTCTGAATCAGAATCTCGCAGTGTTTCTGTGAATAGAT 961 TTTTTTGTAAATATGACCTTTAAGATATTGTATTATGTAAAATATGTATATACCTTTTTTTGTAGGTCACAACAACTCAT 1041 TTTTACAGAGTTTGTGAAGCTAAATATTTAACATTGTTGATTTCAGTAAGCTGTGTGGTGAGGCTACCAGTGGAAGAGAC 1121 ATCCCTTGACTTTTGTGGCCTGGGGGAGGGGTAGTGCTCCACAGCTTTTCCTTCCCCACCCCCCAGCCTTAGATGCCTCG 1201 CTCTTTTCAATCTCTTAATCTAAATGCTTTTTAAAGAGATTATTTGTTTAGATGTAGGCATTTTAATTTTTTAAAAATTC 1281 CTCTACCAGAACTAAGCACTTTGTTAATTTGGGGGGAAAGAATAGATATGGGGAAATAAACTTAAAAAAAAATCAGGAAT 1361 TTAAAAAAACGAGCAATTTGAAGAGAATCTTTTGGATTTTAAGCAGTCCGAAATAATAGCAATTCATGGGCTGTGTGTGT 1441 GTGTGTATGTGTGTGTGTGTGTGTGTATGTTTAATTATGTTACCTTTTCATCCCCTTTAGGAGCGTTTTCAGATTTTGGT 1521 TGCTAAGACCTGAATCCCATATTGAGATCTCGAGTAGAATCCTTGGTGTGGTTTCTGGTGTCTGCTCAGCTGTCCCCTCA 1601 TTCTACTAATGTGATGCTTTCATTATGTCCCTGTGGATTAGAATAGTGTCAGTTATTTCTTAAGTAACTCAGTACCCAGA 1681 ACAGCCAGTTTTACTGTGATTCAGAGCCACAGTCTAACTGAGCACCTTTTAAACCCCTCCCTCTTCTGCCCCCTACCACT 1761 TTTCTGCTGTTGCCTCTCTTTGACACCTGTTTTAGTCAGTTGGGAGGAAGGGAAAAATCAAGTTTAATTCCCTTTATCTG 1841 GGTTAATTCATTTGGTTCAAATAGTTGACGGAATTGGGTTTCTGAATGTCTGTGAATTTCAGAGGTCTCTGCTAGCCTTG 1921 GTATCATTTTCTAGCAATAACTGAGAGCCAGTTAATTTTAAGAATTTCACACATTTAGCCAATCTTTCTAGATGTCTCTG 2001 AAGGTAAGATCATTTAATATCTTTGATATGCTTACGAGTAAGTGAATCCTGATTATTTCCAGACCCACCACCAGAGTGGA 2081 TCTTATTTTCAAAGCAGTATAGACAATTATGAGTTTGCCCTCTTTCCCCTACCAAGTTCAAAATATATCTAAGAAAGATT 2161 GTAAATCCGAAAACTTCCATTGTAGTGGCCTGTGCTTTTCAGATAGTATACTCTCCTGTTTGGAGACAGAGGAAGAACCA 2241 GGTCAGTCTGTCTCTTTTTCAGCTCAATTGTATCTGACCCTTCTTTAAGTTATGTGTGTGGGGAGAAATAGAATGGTGCT 2321 CTTATCTTTCTTGACTTTAAAAAAATTATTAAAAACAAAAAAAAAATAAATTTTTTTGCAATCCTTTCCTCAGACCTGGC 2401 TCCAGGCTAACTGGAAGGCAGCACTCCCTTTTTTATATAGTAGAAAAATGAAGTTTATTATAAGTTTTTATATTTTCTAC 2481 TTGTTCATTTGGTGCAAACTCAAGATTTCTTTTAATAGGTGCAGTCTTTGAGATAATTTGTTTTTACCTGTATTGCCCTT 2561 TATCTTTTTTAGGTAATTCTTTGTACTCCTGCTGTCTACCTCTCCTCACACCCCAGCACCCCCCATTTTTTCAAACCTTG 2641 GTATCTGTTGGGTGAACAGTATAATCTTTTCATCTGCTTTTAGAATGTGGGATATTTCCAGTACCTACTTTTTTTTTTTT 2721 TTTTTGCTGAATCCAAAGATATATAAATAAAATATATATATTTTATAAAGATCAGAATGATATAAAGGAGATACATGTTT 2801 CTTCCTTTAAAAAATAAACGGAAGTTACATTGTTAATGTTCATATTATGATGCCACTTTTCTAAACTGCATCTGGATTGA 2881 AAGGTGTAAATATCAATAACAGTGCTACTTAGTTATCAGTATTTAATATCTGAGGTGAGTTGGGGGTATCTATATTAGGG 2961 GTAGGGTATTACAGAAGATAATTGGCTTGATGTCCTAGAAGTTCTTTGATCCAGAGGTGGGTGCAGCTGAAAGTAAACAG 3041 AATGGATTGCCAGTTACATGTATGCCTGCCCAGTTCCCTTTTTATTTGCAGAAGCTGTGAGTTTTGTTCACAATTAGGTT 3121 CCTAGGAGCAAAACCTCAAGGATTGATTTATTGTTTTCAACTCCAAGGCACACTGTTAATAAACGAGCAGGGTGTTTTCT 3201 CTCTTCCTTTCTAATATATGGAGTTTCGAAGAATAAAATATGAGAGCAATATTTAAATTCTCAGGAATTGACTTATACTC 3281 TTGAGAATGAATTCAGTTTCAATCAAGTTTACATTATGTTGCTTAAAAAAATAGAAATTATTCTTTATCTTGCAAAGAAT 3361 TGAAACCACATGAAATGACTTATGGGGGATGGTGAGCTGTGACTGCTTTGCTGACCATTTTGGATGTCATTGTAAATAAA 3441 GGTTTCTATTTAAAATTGGA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
miRNA:Target | ---- | |||||||||
Validation Method |
|
|||||||||
Conditions | MCF7 | |||||||||
Location of target site | 3'UTR | |||||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | |||||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in SRR1045082. RNA binding protein: AGO2. Condition:Untreated
... - Farazi TA; Ten Hoeve JJ; Brown M; et al., 2014, Genome biology. |
|||||||||
miRNA-target interactions (Provided by authors) |
|
|||||||||
Article |
- Farazi TA; Ten Hoeve JJ; Brown M; et al. - Genome biology, 2014
BACKGROUND: Various microRNAs (miRNAs) are up- or downregulated in tumors. However, the repression of cognate miRNA targets responsible for the phenotypic effects of this dysregulation in patients remains largely unexplored. To define miRNA targets and associated pathways, together with their relationship to outcome in breast cancer, we integrated patient-paired miRNA-mRNA expression data with a set of validated miRNA targets and pathway inference. RESULTS: To generate a biochemically-validated set of miRNA-binding sites, we performed argonaute-2 photoactivatable-ribonucleoside-enhanced crosslinking and immunoprecipitation (AGO2-PAR-CLIP) in MCF7 cells. We then defined putative miRNA-target interactions using a computational model, which ranked and selected additional TargetScan-predicted interactions based on features of our AGO2-PAR-CLIP binding-site data. We subselected modeled interactions according to the abundance of their constituent miRNA and mRNA transcripts in tumors, and we took advantage of the variability of miRNA expression within molecular subtypes to detect miRNA repression. Interestingly, our data suggest that miRNA families control subtype-specific pathways; for example, miR-17, miR-19a, miR-25, and miR-200b show high miRNA regulatory activity in the triple-negative, basal-like subtype, whereas miR-22 and miR-24 do so in the HER2 subtype. An independent dataset validated our findings for miR-17 and miR-25, and showed a correlation between the expression levels of miR-182 targets and overall patient survival. Pathway analysis associated miR-17, miR-19a, and miR-200b with leukocyte transendothelial migration. CONCLUSIONS: We combined PAR-CLIP data with patient expression data to predict regulatory miRNAs, revealing potential therapeutic targets and prognostic markers in breast cancer.
LinkOut: [PMID: 24398324]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HCT116 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in ERX177600. RNA binding protein: AGO2. Condition:p53_V_Ago_CLIP_2_2
PAR-CLIP data was present in ERX177606. RNA binding protein: AGO2. Condition:KO_V_AGO_CLIP_2_8
PAR-CLIP data was present in ERX177612. RNA binding protein: AGO2. Condition:p53_V_AGO_CLIP_3_2
PAR-CLIP data was present in ERX177613. RNA binding protein: AGO2. Condition:KO_D_AGO_CLIP_3_3
PAR-CLIP data was present in ERX177618. RNA binding protein: AGO2. Condition:KO_V_AGO_CLIP_3_8
PAR-CLIP data was present in ERX177624. RNA binding protein: AGO2. Condition:p53_V_AGO_CLIP_4_2
PAR-CLIP data was present in ERX177625. RNA binding protein: AGO2. Condition:KO_D_AGO_CLIP_4_3
PAR-CLIP data was present in ERX177630. RNA binding protein: AGO2. Condition:KO_V_AGO_CLIP_4_8
PAR-CLIP data was present in ERX177633. RNA binding protein: AGO2. Condition:KO_D_AGO_CLIP_4_11
... - Krell J; Stebbing J; Carissimi C; Dabrowska et al., 2016, Genome research. |
Article |
- Krell J; Stebbing J; Carissimi C; Dabrowska et al. - Genome research, 2016
DNA damage activates TP53-regulated surveillance mechanisms that are crucial in suppressing tumorigenesis. TP53 orchestrates these responses directly by transcriptionally modulating genes, including microRNAs (miRNAs), and by regulating miRNA biogenesis through interacting with the DROSHA complex. However, whether the association between miRNAs and AGO2 is regulated following DNA damage is not yet known. Here, we show that, following DNA damage, TP53 interacts with AGO2 to induce or reduce AGO2's association of a subset of miRNAs, including multiple let-7 family members. Furthermore, we show that specific mutations in TP53 decrease rather than increase the association of let-7 family miRNAs, reducing their activity without preventing TP53 from interacting with AGO2. This is consistent with the oncogenic properties of these mutants. Using AGO2 RIP-seq and PAR-CLIP-seq, we show that the DNA damage-induced increase in binding of let-7 family members to the RISC complex is functional. We unambiguously determine the global miRNA-mRNA interaction networks involved in the DNA damage response, validating them through the identification of miRNA-target chimeras formed by endogenous ligation reactions. We find that the target complementary region of the let-7 seed tends to have highly fixed positions and more variable ones. Additionally, we observe that miRNAs, whose cellular abundance or differential association with AGO2 is regulated by TP53, are involved in an intricate network of regulatory feedback and feedforward circuits. TP53-mediated regulation of AGO2-miRNA interaction represents a new mechanism of miRNA regulation in carcinogenesis.
LinkOut: [PMID: 26701625]
|
CLIP-seq Support 1 for dataset SRR1045082 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | MCF7 / Untreated |
Location of target site | ENST00000341724.6 | 3UTR | UACUCCUGCUGUCUACCUCUCCUCACACCCCAG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 24398324 / SRX388831 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
67 hsa-miR-6737-5p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT066215 | MARCH9 | membrane associated ring-CH-type finger 9 | 2 | 2 | ||||||||
MIRT074413 | TNRC6A | trinucleotide repeat containing 6A | 2 | 2 | ||||||||
MIRT125300 | MID1IP1 | MID1 interacting protein 1 | 2 | 2 | ||||||||
MIRT153951 | NCOA3 | nuclear receptor coactivator 3 | 2 | 2 | ||||||||
MIRT452776 | FAM136A | family with sequence similarity 136 member A | 2 | 2 | ||||||||
MIRT452977 | CABP4 | calcium binding protein 4 | 2 | 2 | ||||||||
MIRT454128 | FOXRED2 | FAD dependent oxidoreductase domain containing 2 | 2 | 2 | ||||||||
MIRT455242 | DDX39B | DExD-box helicase 39B | 2 | 10 | ||||||||
MIRT459007 | UQCRH | ubiquinol-cytochrome c reductase hinge protein | 2 | 2 | ||||||||
MIRT459463 | MUC17 | mucin 17, cell surface associated | 2 | 4 | ||||||||
MIRT460871 | UBE2S | ubiquitin conjugating enzyme E2 S | 2 | 2 | ||||||||
MIRT461264 | COX10 | COX10, heme A:farnesyltransferase cytochrome c oxidase assembly factor | 2 | 2 | ||||||||
MIRT464540 | UBTF | upstream binding transcription factor, RNA polymerase I | 2 | 2 | ||||||||
MIRT465268 | TRIM28 | tripartite motif containing 28 | 2 | 2 | ||||||||
MIRT465871 | TMEM43 | transmembrane protein 43 | 2 | 4 | ||||||||
MIRT466228 | TMED10 | transmembrane p24 trafficking protein 10 | 2 | 2 | ||||||||
MIRT468417 | SETD1B | SET domain containing 1B | 2 | 2 | ||||||||
MIRT468684 | SEC22C | SEC22 homolog C, vesicle trafficking protein | 2 | 4 | ||||||||
MIRT473399 | MDM4 | MDM4, p53 regulator | 2 | 2 | ||||||||
MIRT473517 | MAX | MYC associated factor X | 2 | 2 | ||||||||
MIRT474511 | KLHDC8A | kelch domain containing 8A | 2 | 2 | ||||||||
MIRT475801 | HDGF | heparin binding growth factor | 2 | 2 | ||||||||
MIRT479493 | CDH6 | cadherin 6 | 2 | 2 | ||||||||
MIRT480770 | BMP2 | bone morphogenetic protein 2 | 2 | 2 | ||||||||
MIRT481418 | ASB6 | ankyrin repeat and SOCS box containing 6 | 2 | 2 | ||||||||
MIRT482966 | CSTF2 | cleavage stimulation factor subunit 2 | 2 | 2 | ||||||||
MIRT483380 | SPATA6 | spermatogenesis associated 6 | 2 | 4 | ||||||||
MIRT483677 | CYP11A1 | cytochrome P450 family 11 subfamily A member 1 | 2 | 2 | ||||||||
MIRT484328 | EPN1 | epsin 1 | 2 | 4 | ||||||||
MIRT484963 | UCK1 | uridine-cytidine kinase 1 | 2 | 2 | ||||||||
MIRT485908 | PGPEP1 | pyroglutamyl-peptidase I | 2 | 4 | ||||||||
MIRT488149 | PRRC2B | proline rich coiled-coil 2B | 2 | 4 | ||||||||
MIRT488943 | CYP2W1 | cytochrome P450 family 2 subfamily W member 1 | 2 | 6 | ||||||||
MIRT491835 | ZBTB7A | zinc finger and BTB domain containing 7A | 2 | 4 | ||||||||
MIRT493026 | NAA50 | N(alpha)-acetyltransferase 50, NatE catalytic subunit | 2 | 2 | ||||||||
MIRT499374 | PLCG2 | phospholipase C gamma 2 | 2 | 11 | ||||||||
MIRT499723 | USH1G | USH1 protein network component sans | 2 | 4 | ||||||||
MIRT500349 | ZNF385A | zinc finger protein 385A | 2 | 2 | ||||||||
MIRT509574 | HIST2H2AB | histone cluster 2 H2A family member b | 2 | 4 | ||||||||
MIRT512794 | GLRX | glutaredoxin | 2 | 2 | ||||||||
MIRT513291 | SETBP1 | SET binding protein 1 | 2 | 2 | ||||||||
MIRT515697 | ZNF321P | zinc finger protein 321, pseudogene | 2 | 2 | ||||||||
MIRT518255 | LEAP2 | liver enriched antimicrobial peptide 2 | 2 | 2 | ||||||||
MIRT522026 | PAQR3 | progestin and adipoQ receptor family member 3 | 2 | 4 | ||||||||
MIRT523169 | HIST3H3 | histone cluster 3 H3 | 2 | 2 | ||||||||
MIRT524036 | DNAJC8 | DnaJ heat shock protein family (Hsp40) member C8 | 2 | 2 | ||||||||
MIRT533476 | TRIM71 | tripartite motif containing 71 | 2 | 2 | ||||||||
MIRT541488 | ADM | adrenomedullin | 2 | 2 | ||||||||
MIRT553987 | SRPR | SRP receptor alpha subunit | 2 | 2 | ||||||||
MIRT571445 | YKT6 | YKT6 v-SNARE homolog | 2 | 2 | ||||||||
MIRT574889 | Plcg2 | phospholipase C, gamma 2 | 2 | 7 | ||||||||
MIRT607544 | GLI2 | GLI family zinc finger 2 | 2 | 2 | ||||||||
MIRT607688 | MAPK10 | mitogen-activated protein kinase 10 | 2 | 2 | ||||||||
MIRT610072 | CRLF1 | cytokine receptor like factor 1 | 2 | 2 | ||||||||
MIRT610573 | CACUL1 | CDK2 associated cullin domain 1 | 2 | 2 | ||||||||
MIRT614041 | THBS2 | thrombospondin 2 | 2 | 2 | ||||||||
MIRT626318 | LRTOMT | leucine rich transmembrane and O-methyltransferase domain containing | 2 | 2 | ||||||||
MIRT634005 | RIF1 | replication timing regulatory factor 1 | 2 | 2 | ||||||||
MIRT639619 | FGF19 | fibroblast growth factor 19 | 2 | 2 | ||||||||
MIRT647343 | RPH3AL | rabphilin 3A like (without C2 domains) | 2 | 2 | ||||||||
MIRT689704 | ATXN2 | ataxin 2 | 2 | 2 | ||||||||
MIRT691170 | APOL6 | apolipoprotein L6 | 2 | 2 | ||||||||
MIRT693165 | NPR1 | natriuretic peptide receptor 1 | 2 | 2 | ||||||||
MIRT711727 | NUPL2 | nucleoporin like 2 | 2 | 2 | ||||||||
MIRT711806 | ELN | elastin | 2 | 2 | ||||||||
MIRT721546 | FXN | frataxin | 2 | 2 | ||||||||
MIRT722979 | GDE1 | glycerophosphodiester phosphodiesterase 1 | 2 | 2 |
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|